COX inhibitors and bone: A safer impact on osteoblasts by NO-releasing NSAIDs

Publication date: Available online 7 July 2018Source: Life SciencesAuthor(s): Maria Cristina Aisa, Alessandro Datti, Antonio Orlacchio, Gian Carlo Di RenzoAbstractNonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for the treatment of pain and inflammation. Although it is well known that NSAIDs can suppress bone growth, remodelling and repair, they are largely used post-operatively and post-traumatically to achieve analgesia and reduce inflammation in bone tissue.AimsThe impact of two NO-releasing, non-selective NSAIDs, NCX-4016 and HCT-3012 (NO-derivatives of Aspirin and Naproxen, respectively) on osteoblasts were evaluated and compared to the non-selective, parent chemicals and to the COX-2-selective inhibitor Celecoxib.Main methodsUsing MG-63 osteoblast-like cells, we considered proliferation, the early and late stage of differentiation, and the activity of proteinases thought to be involved in osteoid degradation, a preliminary fundamental event of bone remodelling.Key findingsUnlike Aspirin, Naproxen and Celecoxib, the two NO-NSAIDs did not alter proliferation and differentiation of osteoblasts. They also reduced the activity of plasminogen activator, metalloproteinases, and cathepsin B. Similar inhibitory effects against these proteinases were recapitulated by the NO-donor sodium nitroprusside, thereby suggesting a NO-mediated mechanism.SignificanceDue to a differential effect on cell proliferation and differentiation, the two NO-NSAIDs exhibit a safe...
Source: Life Sciences - Category: Biology Source Type: research